Sunday, March 21, 2010
The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review
Centre for Review and Dissemination - Database of Abstracts of Reviews of Effects (DARE)
To determine the efficacy of specialised care for patients with ovarian cancer.
Authors' conclusions:The outcome of ovarian cancer was better when treatment was provided in specialised settings (gynecologic oncologists or in specialised hospitals) than that provided in non-specialised settings.
"Given the limitations and the lack of reported methodology in the review process, although the results appeared promising the authors conclusion appears to be overstated."
OKLAHOMA CITY/EDMOND Note: includes information on womens' health including gynecologic oncology
Medical News March 21st : SGO: Hunt for Ovarian Regimen Focuses on Carboplatin - in Meeting Coverage, SGO
" HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of his “Forsythe Immune Therapy” (FIT).
As previously announced, James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Board of Directors and Head of the Scientific Advisory Board, was featured in Suzanne Somers’ book Knockout. Due to the overwhelming response to the information and protocol featured in Ms. Somers’ book, Dr. Forsythe’s clinic has become inundated with new patient requests and referrals. Due to this dramatic increase in both new patient inquiries and volume, it has become necessary to increase the staff at Dr Forsythe’s facility, The Cancer Screening and Treatment Center of Nevada."
March 9, 2010
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC)today announced that Dr. James Forsythe, MD, HMD, is experiencing continuous success with his Forsythe Immune Therapy (FIT) Protocol. Dr. James Forsythe, MD, HMD, is a board certified oncologist and a member of HST Global Inc.’s Board of Directors and Scientific Advisory Board.
Dr. Forsythe’s existing study is meeting with 70-80% efficacy in clinical treatment of Stage IV cancers in a test of 450 patients. The highlight of the study is in stage IV prostate cancer where they have met with 86% efficacy with prostate cancer patients over 55 months through the application of his "FIT" Protocol.
Ronald Howell President and CEO of HST Global, Inc. stated, "We are encouraged by the continued success Dr. Forsythe is experiencing with his FIT protocol. The updated study results demonstrate the efficacy of the FIT Protocol."
Note: includes numerous comments by a variety of healthcare professional disciplines
Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is a recently developed antiepileptic drug also used in management of chronic neuropathic pain conditions.
Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia. A minority of patients will have substantial benefit with pregabalin, and more will have moderate benefit. Many will have no or trivial benefit, or will discontinue because of adverse events. Individualisation of treatment is needed to maximise pain relief and minimise adverse events. There is no evidence to support the use of pregabalin in acute pain scenarios.